| abstract |
The compounds of formula I are claimed wherein: the dotted line is either a single or double bond; W is O or S; B is optionally substituted alkylene; R is H, OH, R' or OR'; G1 is halogen, a trihaloalkylsulphonyloxy, carboxy, formyl, cyano, R1, -CO-R1, -O-CO-R1 wherein G11 is H or G11 and R form together with the carbons to which they are attached an optionally saturated, optionally substituted ring of 5-7 members containing an oxygen atom or G1 is H wherein G11 is trihaloalkylsulphonyloxy, carboxy, formyl, cyano, R1, -CO-R1, -O-CO-R1; R' is optionally substituted alkyl, alkenyl, alkynyl, aryl, biphenyl, heteroaryl or cycloalkyl or a trihaloalkylsulphonyl; R1 is optionally substituted alkyl, alkenyl, alkynyl, aryl, biphenyl, heteroaryl or cycloalkyl; G2 is -N(R2)-C(=X)-R20, -N(R2)-C(=X)-NH-R21 or -C(=X)-N(R2)(R22); X is O or S; R2 is H or alkyl; R20-R22 are independently optionally substituted alkyl, alkenyl, alkynyl, aryl, biphenyl, heteroaryl or cycloalkyl limited by the provisos given in the specification. A process for preparing a compound of formula I is claimed. A pharmaceutical composition containing a compound of formula I useful in the treatment of disorders associated with melationinergic system is claimed. |